BUFFALO GROVE, Ill., May 20, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.
Mr. Simes will present at The Marcum MicroCap Conference on Thursday May 28, 2015 in New York City at 10:30am ET. The presentation will be webcast and available for 90 days at http://wsw.com/webcast/marcum3/resx.
Also on Thursday May 28, 2015, Mr. Simes will present at the SeeThruEquity 4th Annual Microcap Conference in New York City, NY at 2:00pm ET. There will be no webcast of this presentation available.
About RestorGenex Corporation
RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.